Phase 1 × Immune System Diseases × Clear all
NCT06271252 2024-08-02

A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study

OriCell Therapeutics Co., Ltd.

Phase 1 Recruiting
81 enrolled
NCT04309084 2023-02-16

Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma

Celularity Incorporated

Phase 1 Unknown
29 enrolled